438
Views
6
CrossRef citations to date
0
Altmetric
Review

Leukapheresis and Hyperleukocytosis, Past and Future

ORCID Icon, , , ORCID Icon &
Pages 3457-3467 | Published online: 14 Jul 2021

References

  • Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduction and overview of therapeutic apheresis. J Clin Apher. 2010;25(5):240–249. doi:10.1002/jca.20247
  • Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol. 2017;11(8):749–758. doi:10.1080/17474124.2017.1341309
  • Rowe JM, Lichtman MA. Hyperleukocytosis and leukostasis: common features of childhood chronic myelogenous leukemia. Blood. 1984;63(5):1230–1234. doi:10.1182/blood.V63.5.1230.1230
  • Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. Leukocytoreduction for acute leukemia. Ther Apheresis. 2002;6(1):15–23. doi:10.1046/j.1526-0968.2002.00402.x
  • Buresh A, Perentesis J, Rimsza L, et al. Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia. 2005;19(2):308–310. doi:10.1038/sj.leu.2403569
  • Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10):1993–2002. doi:10.1182/blood-2012-04-424440
  • Ali AM, Mirrakhimov AE, Abboud CN, Cashen AF. Leukostasis in adult acute hyperleukocytic leukemia: a clinician’s digest. Hematol Oncol. 2016;34(2):69–78. doi:10.1002/hon.2292
  • Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014;38(4):460–468. doi:10.1016/j.leukres.2014.01.004
  • Stoecklein NH, Fischer JC, Niederacher D, Terstappen LW. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. Expert Rev Mol Diagn. 2016;16(2):147–164. doi:10.1586/14737159.2016.1123095
  • Fischer JC, Niederacher D, Topp SA, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A. 2013;110(41):16580–16585. doi:10.1073/pnas.1313594110
  • Aqui N, O’Doherty U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. Hematol Am Soc Hematol Educ Prog. 2014;2014(1):457–460. doi:10.1182/asheducation-2014.1.457
  • Tullis JL. Separation and purification of leukocytes and platelets. Blood. 1952;7(9):891–896. doi:10.1182/blood.V7.9.891.891
  • Batchelor WH, D’Hont M, Driscoll S, et al. New principle of closed system centrifugation. Science (New York, NY). 1956;124(3226):792–797. doi:10.1126/science.124.3226.792
  • Buckner D, Eisel R, Perry S. Blood cell separation in the dog by continuous flow centrifugation. Blood. 1968;31(5):653–672. doi:10.1182/blood.V31.5.653.653
  • Djerassi I, Kim JS, Mitrakul C, Suvansri U, Ciesielka W. Filtration leukapheresis for separation and concentration of transfusable amounts of normal human granulocytes. J Med. 1970;1(6):358–364.
  • Herzig GP, Root RK, Graw RG Jr. Granulocyte collection by continuous-flow filtration leukapheresis. Blood. 1972;39(4):554–567. doi:10.1182/blood.V39.4.554.554
  • Buckner D, Graw RG Jr, Eisel RJ, Henderson ES, Perry S. Leukapheresis by continuous flow centrifugation (CFC) in patients with chronic myelocytic leukemia (CML). Blood. 1969;33(2):353–369. doi:10.1182/blood.V33.2.353.353
  • Sethu P, Sin A, Toner M. Microfluidic diffusive filter for apheresis (leukapheresis). Lab Chip. 2006;6(1):83–89. doi:10.1039/B512049G
  • López-Pereira P, Sola Aparicio E, Vicuña Andrés I, et al. Retrospective comparison between COBE SPECTRA and SPECTRA OPTIA apheresis systems for hematopoietic progenitor cells collection for autologous and allogeneic transplantation in a single center. J Clin Apher. 2020;35(5):453–459. doi:10.1002/jca.21826
  • Duvall D. Therapeutic cytapheresis: too many platelets, too many white blood cells. J Clin Apher. 2011;26(1):47–52. doi:10.1002/jca.20266
  • Augustsson P, Karlsen JT, Su HW, Bruus H, Voldman J. Iso-acoustic focusing of cells for size-insensitive acousto-mechanical phenotyping. Nat Commun. 2016;7:11556. doi:10.1038/ncomms11556
  • Dykes J, Lenshof A, Astrand-Grundstrom IB, Laurell T, Scheding S. Efficient removal of platelets from peripheral blood progenitor cell products using a novel micro-chip based acoustophoretic platform. PLoS One. 2011;6(8):e23074. doi:10.1371/journal.pone.0023074
  • Nam J, Lim H, Kim D, Shin S. Separation of platelets from whole blood using standing surface acoustic waves in a microchannel. Lab Chip. 2011;11(19):3361–3364. doi:10.1039/c1lc20346k
  • Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18. doi:10.3109/10428190009053534
  • Altuntas F, Sari I, Kocyigit I, et al. Comparison of Plateletpheresis on the Fenwal Amicus and Fresenius Com Tec cell separators. Transfusion Med Hemother. 2008;35(5):368–373. doi:10.1159/000151351
  • Ruggiero A, Rizzo D, Amato M, Riccardi R. Management of hyperleukocytosis. Curr Treat Options Oncol. 2016;17(2):7. doi:10.1007/s11864-015-0387-8
  • Hölig K, Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia. Transfusion Med Hemother. 2012;39(4):241–245. doi:10.1159/000341805
  • Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26(3):117–122. doi:10.1016/j.blre.2012.01.003
  • Schulz M, Bialleck H, Thorausch K, et al. Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems. Transfusion. 2014;54(6):1622–1629. doi:10.1111/trf.12506
  • Andree KC, Mentink A, Zeune LL, et al. Toward a real liquid biopsy in metastatic breast and prostate cancer: diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). Int J Cancer. 2018;143(10):2584–2591. doi:10.1002/ijc.31752
  • Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354.
  • Eberhardson M, Marits P, Jones M, et al. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin immunol. 2013;149(1):73–82. doi:10.1016/j.clim.2013.05.021
  • Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol. 2014;20(29):9699–9715. doi:10.3748/wjg.v20.i29.9699
  • Jin Y, Guo S, Cui Q, et al. A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia. Sci Rep. 2018;8(1):294. doi:10.1038/s41598-017-17534-4
  • Powell BL, Gregory BW, Evans JK, et al. Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia. Leukemia. 1991;5(12):1037–1042.
  • Bruserud Ø, Liseth K, Stamnesfet S, et al. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfusion Med. 2013;23(6):397–406. doi:10.1111/tme.12067
  • Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children’s Oncology Group. Haematologica. 2012;97(11):1770–1773. doi:10.3324/haematol.2012.065490
  • Bojanic I, Mazic S, Rajic L, Jakovljevic G, Stepan J, Cepulic BG. Large volume leukapheresis is efficient and safe even in small children up to 15 kg body weight. Blood Transfusion = Trasfusione Del Sangue. 2017;15(1):85–92.
  • Galera P, Haynes S, Sulmasy P, et al. Physiological measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnant woman with chronic myelogenous leukemia. J Clin Apher. 2016;31(4):393–397. doi:10.1002/jca.21410
  • Staley EM, Simmons SC, Feldman AZ, et al. Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature. Transfusion. 2018;58(2):456–460. doi:10.1111/trf.14448
  • Yellu M, Pinkard S, Ghose A, Medlin S. CML in pregnancy: a case report using leukapheresis and literature review. Transfusion Apheresis Sci. 2015;53(3):289–292.
  • Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017;10(2):147–154. doi:10.1080/17474086.2017.1270754
  • Allon M. Current management of vascular access. Clin J Am Soc Nephrol. 2007;2(4):786–800. doi:10.2215/CJN.00860207
  • Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854. doi:10.1056/NEJMra0904569
  • Schlenke P, Frohn C, Steinhardt MM, Kirchner H, Kluter H. Clinically relevant hypokalaemia, hypocalcaemia, and loss of hemoglobin and platelets during stem cell apheresis. J Clin Apher. 2000;15(4):230–235. doi:10.1002/1098-1101(2000)15:4<230::AID-JCA3>3.0.CO;2-B
  • Punzel M, Kozlova A, Quade A, Schmidt AH, Smith R. Evolution of MNC and lymphocyte collection settings employing different Spectra Optia(®) Leukapheresis systems. Vox Sang. 2017;112(6):586–594. doi:10.1111/vox.12540
  • Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–1891. doi:10.1182/blood-2008-04-150250
  • Rollig C, How EG. I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246–3252. doi:10.1182/blood-2014-10-551507
  • Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997;98(2):433–436. doi:10.1046/j.1365-2141.1997.1943011.x
  • Thiébaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol. 2000;79(9):501–506. doi:10.1007/s002770000162
  • Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001;42(1–2):67–73. doi:10.3109/10428190109097677
  • Chang MC, Chen TY, Tang JL, et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007;82(11):976–980. doi:10.1002/ajh.20939
  • Choi MH, Choe YH, Park Y, et al. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion. 2018;58(1):208–216. doi:10.1111/trf.14329
  • Nan X, Qin Q, Gentille C, et al. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. Leuk Lymphoma. 2017;58(9):1–11. doi:10.1080/10428194.2016.1277386
  • Wong GC. Hyperleukocytosis in acute myeloid leukemia patients is associated with high 30-day mortality which is not improved with leukapheresis. Ann Hematol. 2015;94(12):2067–2068. doi:10.1007/s00277-015-2472-2
  • Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007;47(10):1843–1850. doi:10.1111/j.1537-2995.2007.01406.x
  • Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014;9(4):e95062. doi:10.1371/journal.pone.0095062
  • Stahl M, Shallis RM, Wei W, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020;34(12):3149–3160. doi:10.1038/s41375-020-0783-3
  • Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol. 2020;13(5):489–499. doi:10.1080/17474086.2020.1751609
  • Sietsma H, Kamps WA, Dontje B, et al. Leukemia-induced bone marrow depression: effects of gangliosides on erythroid cell production. Int J Cancer. 1999;82(1):92–97. doi:10.1002/(SICI)1097-0215(19990702)82:1<92::AID-IJC16>3.0.CO;2-J
  • Shahrabi S, Behzad MM, Jaseb K, Saki N. Thrombocytopenia in leukemia: pathogenesis and prognosis. Histol Histopathol. 2018;33(9):895–908.
  • Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284. doi:10.1002/jca.21276